Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Innovo Immune Newcastle Vaccine is a veterinary vaccine developed by Virogen, Inc. to protect poultry against Newcastle disease, a highly contagious and often fatal viral infection. The vaccine is designed to elicit a protective immune response, thereby reducing mortality and preventing the severe tissue lesions characteristic of the disease in chickens and other susceptible birds. Virogen, a Minnesota-based corporation, holds the patent for the vaccine and has secured European Union manufacturing approval and licensing. The product is commercialized internationally, with established distribution networks and purchase orders in Asian and Middle Eastern markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Innovo Immune Newcastle Vaccine.